The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abacavir-Lamivudine-Zidovudine vs Indinavir-Lamivudine-Zidovudine in Antiretroviral-Naive HIV-Infected Adults<SUBTITLE>A Randomized Equivalence Trial</SUBTITLE>
Abstract
Context Abacavir, a nucleoside analogue, has demonstrated suppression of human immunodeficiency virus (HIV) replication alone and in combination therapy. However, the role of abacavir in a triple nucleoside combination regimen has not been evaluated against a standard protease inhibitor-containing regimen for initial antiretroviral treatment. Objective To evaluate antiretroviral equivalence and safety of an abacavir-lamivudine-zidovudine regimen compared with an indinavir-lamivudine-zidovudine regimen. Design and setting A multicenter, phase 3, randomized, double-blind trial with an enrollment period from August 1997 to June 1998, with follow-up through 48 weeks at 73 clinical research units in the United States, Canada, Australia, and Europe. Patients Five hundred sixty-two antiretroviral-naive, HIV-infected adults with a plasma HIV RNA level of at least 10 000 copies/mL and a CD4 cell count of at least 100 x 10(6)/L. Interventions Patients were stratified by baseline HIV RNA level and randomly assigned to receive a combination tablet containing 150 mg of lamivudine and 300 mg of zidovudine twice daily plus either 300 mg of abacavir twice daily and indinavir placebo or 800 mg of indinavir every 8 hours daily plus abacavir placebo. After 16 weeks, patients with confirmed HIV RNA levels greater than 400 copies/mL were eligible to continue receiving randomized treatment or receive open-label therapy. Main outcome measure Virologic suppression, defined as HIV RNA concentration o…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the former, the interest is in the difference between proportions.This is called the absolute risk difference (ARD) and is the measure used in the abacavir-indinavir trial 1 .”
From Understanding Equivalence and Noninferiority Testing (2011) · cites this paper as [1]
Citations
Cites
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,197
Castro, K. G., Ward, J., Slutsker, L., Buehler, J. W., Jaffe, H. W., Berkelman, R. L., & Curran, J. W. (1993) · Clinical Infectious Diseases · doi:10.1093/clinids/17.4.802 · Cited by 4,347
Hammer, S. M., Squires, K., Hughes, M. D., Grimes, J. M., Demeter, L. M., Currier, J. S., Eron, J. J., Feinberg, J., Balfour, H. H., Deyton, L., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371101 · Cited by 2,638
Gulick, R. M., Mellors, J. W., Havlir, D. V., Eron, J. J., Gonzalez, C. J., McMahon, D. K., Richman, D. D., Valentine, F. T., Jonas, L., Meibohm, A. R., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709113371102 · Cited by 1,883
Empirical evidence of design-related bias in studies of diagnostic tests.
Lijmer, J. G. (1999) · JAMA · doi:10.1001/jama.282.11.1061 · Cited by 1,861
Gazzard, B., & on behalf of the BHIVA Treatment Guidelines Writing Group (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2008.00636.x · Cited by 1,090
Carr, A., Samaras, K., Chisholm, D. J., & Cooper, D. A. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03391-1 · Cited by 1,065
Antiretroviral Therapy in Adults
Carpenter, C. C. J., Cooper, D. A., Fischl, M. A., Gatell, J. M., Gazzard, B., Hammer, S. M., Hirsch, M., Jacobsen, D. M., Katzenstein, D. A., Montaner, J. S. G., et al. (2000) · JAMA · doi:10.1001/jama.283.3.381 · Cited by 1,007
Staszewski, S., Morales-Ramirez, J. O., Tashima, K. T., Rachlis, A., Skiest, D. J., Stanford, J., Stryker, R., Johnson, P. C., Labriola, D., Farina, D., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912163412501 · Cited by 993
Self-citation
Cited by
Sorted by citations
Items 201–277 of 277
Duber, H. C., Roberts, D. A., Ikilezi, G., Fullman, N., Gasasira, A. F., Gakidou, E. E., Haakenstad, A., Levine, A. J., & Achan, J. (2016) · Tropical Medicine & International Health · doi:10.1111/tmi.12694 · Cited by 5
Treating Advanced HIV Infection
Boffito, M., Bonora, S., Sinicco, A., Raiteri, R., Milia, M. G., Khoo, S., Hoggard, P. G., Back, D. J., & Perri, G. D. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200311010-00014 · Cited by 5
Colombié, V., Wehrlen-Pugliese, S., Deuffic‐Burban, S., Cuzin, L., Pugliese, P., Katlama, C., Poizot‐Martin, I., Raffi, F., Cabie, A., Dellamonica, P., et al. (2012) · International Journal of STD & AIDS · doi:10.1258/ijsa.2012.011438 · Cited by 4
The DART Trial: 'The Doctor's Dilemma' revisited
Nunes, E. P., Grinsztejn, B. G. J., & Schechter, M. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr020 · Cited by 4
Overview of Antiretroviral Agents in 2005
Stanic, A., & Schneider, T. (2005) · Journal of Pharmacy Practice · doi:10.1177/0897190005278612 · Cited by 4
el Sida, P. D. E. D. G. Y. P. N. S. (2013) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/j.eimc.2013.04.009 · Cited by 5
Deutsch-Österreichische Richtlinien zur Antiretroviralen Therapie der HIV-Infektion
Brockmeyer, N. H., Hoffmann, K. K. P., Reimann, G., Stücker, M., Altmeyer, P. J., & Brodt, R. H. (2000) · Springer eBooks · doi:10.1007/978-3-642-59683-4_153 · Cited by 4
Protease Inhibitor???sparing Regimens
Moyle, G. J. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200306011-00003 · Cited by 4
Antiretroviral therapy: When and what to start—an American perspective
Wilkin, T. J., & Gulick, R. M. (2003) · Current Infectious Disease Reports · doi:10.1007/s11908-003-0012-z · Cited by 4
The Problems Faced When Assessing the Prevalence and Incidence of Antiretroviral-Related Toxicities
Smith, C. J., & Sabin, C. A. (2004) · Antiviral Therapy · doi:10.1177/135965350400900614 · Cited by 4
Sprenger, H. G., Bierman, W. F. W., van der Werf, T. S., Gisolf, E. H., & Richter, C. (2013) · Antiviral Therapy · doi:10.3851/imp2726 · Cited by 3
An empirical demonstration of the need for exact tests
Berger, V. W. (2017) · Journal of Modern Applied Statistical Methods · doi:10.22237/jmasm/1493596920 · Cited by 3
The Ideal Nucleoside/Nucleotide Backbone
Gallant, J. E. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000137006.70999.d3 · Cited by 3
Effets indésirables induits par les traitements antirétroviraux
Lagrange-Xélot, M., & Molina, J. (2005) · La Presse Médicale · doi:10.1016/s0755-4982(05)84227-7 · Cited by 3
Amador, J. T. R., & Peña, M. J. M. (2004) · Anales de Pediatría · doi:10.1016/s1695-4033(04)78260-0 · Cited by 3
The role of NNRTIs in antiretroviral combination therapy: An introduction
Nelson, M. R. (2001) · International Journal of STD & AIDS · doi:10.1258/0956462011924263 · Cited by 3
Antiretroviral Management of Treatment-Naive Patients
Gulick, R. M. (2007) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2007.01.002 · Cited by 3
Estrategias terapéuticas en la infección por el virus de la inmunodeficiencia humana
Barreiro, P., & Soriano, V. (2005) · Medicina Clínica · doi:10.1157/13074743 · Cited by 3
When to start antiretroviral therapy and what to start with—a European perspective
Wit, F. W. N. M., & Reiss, P. (2003) · Current Infectious Disease Reports · doi:10.1007/s11908-003-0013-y · Cited by 3
Treatment of advanced HIV infection
Pulido, F. (2003) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkg065 · Cited by 3
Mastroianni, C. M., d’Ettorre, G., & Vullo, V. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.16.2233 · Cited by 3
Enzymatic Synthesis of Nucleic Acid Derivatives Using Whole Cells
Lewkowicz, E. S., & Iribarren, A. M. (2018) · doi:10.1002/9783527812103.ch3 · Cited by 3
Thrombotic Thrombocytopenic Purpura Associated with Abacavir in a Patient with HIV Infection
Olszewski, A. J., & Shapiro, J. M. (2003) · Journal of Intensive Care Medicine · doi:10.1177/0885066603018003006 · Cited by 2
Kirk, O. (2004) · PubMed · Cited by 2
Incorporating Pharmacogenomics in Drug Development
Yin, O. Q. P., & Vandell, A. G. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812626-4.00003-6 · Cited by 3
Resistance to Nucleoside and Nucleotide Reverse Transcriptase Inhibitors
Shulman, N. S., & Winters, M. A. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-085-0_6 · Cited by 2
Bickel, M., Rickerts, V., Stephan, C., Jacobi, V., Rottmann, C., Dauer, B., Carlebach, A., Thalhammer, A., Miller, V., & Staszweski, S. (2005) · HIV Medicine · doi:10.1111/j.1468-1293.2005.00286.x · Cited by 2
Single-Class Therapy for HIV is Not Optimal Care
Clay, P. G. (2004) · Annals of Pharmacotherapy · doi:10.1345/aph.1e030 · Cited by 2
Initial antiretroviral therapy in chronically-infected HIV-positive adults
Temesgen, Z., Cainelli, F., Warnke, D., & Koirala, J. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.3.595 · Cited by 2
Comparison of the efficacy of HAART: single, dual or triple-class antiretroviral therapy
Paredes, R., Clotet, B., & Ruiz, L. (2004) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7869-2_4 · Cited by 2
The clinical challenges of lifetime HAART
Paredes, R., Sherer, R. D., & Clotet, B. (2008) · doi:10.1093/acprof:oso/9780199225859.003.0026 · Cited by 2
Neely, M. N., Rutstein, R. M., Bianco, G. P. D., Heresi, G. P., Barton, T., WIZNIA, A. A., Wiegand, R. E., Wheeling, J. T., Bohannon, B. A., & Dominguez, K. L. (2013) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0b013e31828e8c09 · Cited by 1
For the ESS40005 Study Team, Fischl, M. A., Burnside, A. F., Farthing, C., Thompson, M., Bellos, N. C., Williams, V. C., Kauf, T. L., Wannamaker, P. G., & Shaefer, M. S. (2003) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.23.14.1432.31944 · Cited by 1
Raffi, F. (2004) · Médecine et Maladies Infectieuses · doi:10.1016/s0399-077x(04)80009-x · Cited by 1
Abacavir: una revisión actualizada sobre sus propiedades y aplicaciones
Martínez, C. L. R., Rodríguez, A. M., Hernández, R. G., Alfonso, Y. B., & del Valle, L. G. (2015) · Revista cubana de farmacia · Cited by 1
Incorporating Pharmacogenomics in Drug Development
Yin, O. Q. P. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-391918-2.00018-4 · Cited by 1
Antiretroviral therapy: When and what to start—An American perspective
Wilkin, T. J., & Gulick, R. M. (2004) · Current HIV/AIDS Reports · doi:10.1007/s11904-004-0009-8 · Cited by 1
Ruane, P. J., Kubota, M. K., Williams, A. L., Arroyo, J. C., Canas, A., Richmond, G. J., Alsop, C., Yau, L., Hessenthaler, S. M., & Hernández, J. E. (2003) · Infectious Diseases in Clinical Practice · doi:10.1097/01.idc.0000104895.16995.8d · Cited by 1
Darunavir/ritonavir monotherapy in clinical practice
Parienti, J. (2010) · AIDS · doi:10.1097/qad.0b013e3283405d2c · Cited by 1
Optimización de la adherencia al tratamiento antirretrovírico
García, P. B., Lahoz, J. G., & Soriano, V. (2003) · Revista Clínica Española · doi:10.1016/s0014-2565(03)71270-3 · Cited by 1
Initiation of antiretroviral therapy
Pozniak, A. (2006) · Current Opinion in Internal Medicine · doi:10.1097/01.coh.0000239852.22614.b1 · Cited by 1
Nassar, N. N., & Keiser, P. H. (2002) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.3.5.619 · Cited by 1
Effect Sizes for Equivalence Testing: Incorporating the Equivalence IntervalPreprint
Gutierrez, N. M., & Cribbie, R. A. (2022) · doi:10.31234/osf.io/5buz9 · Cited by 1
DRUGS FOR DIFFICULT BUGS: AN OVERVIEW OF NEW ANTIBACTERIAL AND ANTIVIRAL AGENTS
Kennedy, N. (2001) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.1177/1478271520013102002 · Cited by 1
Lamivudine/Zidovudine/Abacavir
Moyle, G. J. (2003) · Drugs · doi:10.2165/00003495-200363110-00012
Challenges in the treatment of HIV-1 infected children with highly active antiretroviral therapy
van Rossum, A. M. C. (2002) · EUR Research Repository (Erasmus University Rotterdam)
Toxicodermias en pacientes con síndrome de inmunodeficiencia adquirida
Goiriz, R., & Herrera, J. F. (2008) · Piel · doi:10.1016/s0213-9251(08)71039-6
Cohen, C. J. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200306011-00004
Leal, M., Camacho, Á., Genebat, M., & Rivero, A. (2008) · Enfermedades Infecciosas y Microbiología Clínica · doi:10.1016/s0213-005x(08)76562-5
HIV-Therapie mit dem Nukleosidanalogon Abacavir: Hypersensitivitätsreaktionen und HLA-B57-Status
Tesch, N. (2008) · bonndoc (University of Bonn)
Gallant, J. E., Lim, M. L., & Shaefer, M. S. (2006) · The Journal of Infectious Diseases · doi:10.1086/504299
Bickel, M., Stephan, C., Lennemann, T., Khaykin, P., Nisius, G., Brodt, H. R., Staszewski, S., & Haberl, A. (2010) · Journal of AIDS and HIV Research · doi:10.5897/jahr.9000003
Self-citationTop Ten Research Reports of 2003
Wohl, D. A. (2003)
Trends in the Treatment of HIV Infection
Sequeira, R. P. (2006)
Pharmacogenomics in Drug Discovery, Prospects and Clinical Applicability
Osakwe, O. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802220-7.00010-7
Glenday, K., Petoumenos, K., Law, M. G., & Cooper, D. A. (2008) · doi:10.1093/acprof:oso/9780199225859.003.0006
Care of the Adult Patient with HIV Infection
Horowitz, H. W., & Wormser, G. P. (2004) · Elsevier eBooks · doi:10.1016/b978-012764051-8/50015-9
Antiretroviral therapy and its impact on lipid metabolic parameters
Kanestri, V. G., Kravchenko, A. V., Deulina, M. O., Kanestri, V. G., Kravchenko, A. V., & Deulina, M. O. (2011) · Epidemiology and Infectious Diseases · doi:10.17816/eid40578
Barreiro, P., Simarro, N., & Rodrguez-Nvoa, S. (2006) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0211-3449(06)74337-5
McNicholl, I. R. (2003) · Side effects of drugs annual · doi:10.1016/s0378-6080(03)80036-3
(2013) · Wiley series in probability and statistics · doi:10.1002/9781118458167.refs
Street, A. (2010) · CRC Press eBooks · doi:10.1201/b13787-266
Human Immunodeficiency Virus ( HIV )
(2006) · Wiley Handbook of Current and Emerging Drug Therapies · doi:10.1002/9780470041000.cedt110
A combination drug of abacavir-lamivudine-zidovudine (Trizivir®) for treating HIV infection and AIDS
Shey, M. S., Kongnyuy, E. J., Shang, J. D., & Wiysonge, C. S. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005481
Abacavir- and indinavir-based regimens comparable?
&NA; (2001) · Inpharma Weekly · doi:10.2165/00128413-200112790-00037
ANTIVIRAL DRUGS, INCLUDING IMMUNOGLOBULINS AND INTERFERONS
(2010) · Elsevier eBooks · doi:10.1016/b978-0-444-53272-5.50006-6
(2010) · Progress in Transplantation · doi:10.7182/prtr.20.3.b167521713075750
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00886-6
(2010) · Progress in Transplantation · doi:10.1177/152692481002000302
Schmied, B. (2007) · Springer eBooks · doi:10.1007/978-3-211-69389-6_13
(2006) · Elsevier eBooks · doi:10.1016/b0-44-451005-2/00765-8
Talbot, M. D. (2008) · PubMed Central
Sahloff, E. G. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44037-3.00456-5
HIV Therapeutics: Antiretroviral Drugs and Immune-Based Therapies
Georgiev, V. S. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-297-1_34
A perspective of the history of HAART
Konopnicki, D., & Clumeck, N. (2004) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7869-2_2
Gärtner, M. (2003) · Springer eBooks · doi:10.1007/978-3-7091-3796-3_10
Metadata
- Authors
- Staszewski, S.
- Affiliations
- Goethe University Frankfurt (DE)
- Corresponding author
- Staszewski, Schlomo
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2001-03-07
- Volume
- 285
- Issue
- 9
- Pages
- 1155
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2129710521
- Cited by
- 277
- References
- 38
- Citations by year
- 2026: 1 · 2023: 1 · 2022: 2 · 2020: 2 · 2019: 2 · 2018: 2 · 2017: 2 · 2016: 5 · 2015: 5 · 2014: 5 · 2013: 10 · 2012: 6
- FWCI
- 31.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Keywords
- abacavir, indinavir, lamivudine, zidovudine, HIV infection, antiretroviral-naive patients, triple-drug combination therapy, nucleoside reverse transcriptase inhibitors, protease inhibitors, viral suppression, treatment safety, drug interactions, adverse events, CD4 count, HIV RNA
- MeSH terms
- Abacavir, Adult, Aged, Double-Blind Method, Drug Resistance, Microbial, Female, Genotype, HIV, Humans, Male, Middle Aged, Mutation, Therapeutic Equivalency, Zidovudine, Dideoxynucleosides, HIV Infections, Survival Analysis, HIV Protease Inhibitors, CD4 Lymphocyte Count, Reverse Transcriptase Inhibitors, Lamivudine, Anti-HIV Agents, Indinavir, Viral Load, Antiretroviral Therapy, Highly Active, HIV Reverse Transcriptase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
